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Introduction 
The majority of people with epilepsy become seizure-free with antiepileptic 
medications, but approximately 20-30% will have refractory epilepsy‚ i.e. seizures 
persist despite accurate diagnosis and carefully monitored treatment with antiepileptic 
drugs (1, 2). The chance of responding to medications falls dramatically after failure 
of two drugs (3). Non pharmacological approaches for children with uncontrolled 
epilepsy include epilepsy surgery, the vagal nerve stimulation (VNS) and diet 
therapies. Unfortunately, surgery and VNS are not easily available in developing 
countries; therefore, dietary therapies represent a potentially valuable adjunct to 
other epilepsy treatment. 
The ketogenic diet (KD), which is a high fat, adequate protein and very low-
carbohydrate diet, has been used for many years to treat intractable epilepsy in 
children. The KD has been shown to be effective in retrospective, prospective and 
randomized controlled studies (4-7). Since its introduction in 1921, the traditional 
KD has not changed considerably (8). The KD, however, seems to be difficult to 
introduce to older children and adolescents, and requires highly motivated parents 
in order to successfully maintain this very strict diet.




The aim of the present study was to evaluate the efficacy and tolerability of a 
modified Atkins diet for intractable childhood epilepsy. 
Materials & Methods
Twenty one children with medically intractable epilepsy were enrolled in the 
study. Inclusion criteria were at least four seizures per month and a trial of at 
least three anticonvulsants without becoming seizure-free. The subjects received 
the diet over a 6-month period. 
Results
Three months after diet initiation, 15 patients (71.4%) remained on the diet and 
12 (57.1%) had >50% seizure reduction. Eleven patients (52.4%) completed 
the 6-month study and 8 (38.1%) chose to remain on the diet afterward. At 6 
months, 9 patients (42.8%) had >50% seizure reduction. The diet was more 
effective in cryptogenic epilepsy (p=0.032). Most complications were transient 
and successfully managed by careful follow-up and conservative strategies. 
Conclusion
The modified Atkins diet is an effective and well- tolerated therapy for intractable 
childhood epilepsy.
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The Modified Atkins Diet (MAD) induces ketosis, but 
without fluid, calorie, or protein restriction, nor the 
requirement for fasting, food weighing or hospitalization 
(9). Recently, this diet was shown to be effective and well 
tolerated in children with intractable epilepsy (10-11).
The aim of the present study was to evaluate the 
tolerability and efficacy of treatment with the Modified 
Atkins Diet for six months in children and adolescents 
with medically intractable epilepsy.
Materials & Methods
Twenty-one patients were treated prospectively in a 
hospital based ambulatory clinic at Tabriz Children 
Hospital, Iran, from March 2006 to August 2008. The 
subjects were 21 children in the age range of 4-17 
years, with intractable epilepsy. These children were 
experiencing more than four seizures per month which 
could not be controlled by any combination of three or 
more antiepileptic drugs (AEDs). Patients with evidence 
of metabolic disorders were excluded. Neuroimaging and 
electroencephalogram (EEG) findings were reviewed. 
The subjects were treated with the Modified Atkins Diet 
protocol (Table1) (11). 
For statistical analysis, the etiologies were defined 
as cryptogenic or symptomatic, because a detailed 
classification would reduce the number of patients in each 
category and would reduce the statistical significance 
of each. Antiepileptic drugs were not changed during 
the diet.  To measure the outcome, seizure control was 
assessed based on seizure calendars provided by the 
patients and parents. Efficacy was evaluated based on 
the comparison between the average monthly baseline 
seizure frequency (3 months before diet initiation) and 
seizure frequency after 6 months of using MAD. Control 
was optimal if patients achieved ≥90% reduction in 
seizure frequency and the diet was considered effective 
if seizure control was higher than 50%, compared to 
previous baselines. Because of natural fluctuations in 
these seizure disorders, improved seizure control had to 
be evident for more than 4 weeks.
  Although EEG was obtained from all patients in the 
beginning of diet, response was determined only through 
seizure diary. Differences between proportions were 
statistically tested by Chi-square Fisher’s exact test. 
All other numerical or quantitative comparisons were 
performed using student’s unpaired t-test or Mann-
Whitney U test. All values were two tailed and were 
considered statistically significant at P≤0.05 level. 
Oral and written informed consent was obtained from 
all families prior to the initiation of the study.     This 
study was approved by the Ethics Committee of Tabriz 
University of Medical Sciences.
Results
The 21 enrolled patients (11 males, 10 females) had a 
mean (±SD) age of 10.1(±3.8) years at the beginning of 
the diet and the mean age at seizure onset was 5.9 (±3.5), 
ranging from 0.2 to 13 years. The mean number of 
AEDs tried before diet initiation was 6.9 (±2.5). At diet 
initiation, every child was receiving at least two AEDs. 
Characteristics of patients are shown in Table 2. 
Thirteen patients (61.9%) had cryptogenic and 8 patients 
(38.1%) had symptomatic epilepsy.
Efficacy and tolerability
Patients maintained on the Modified Atkins Diet for a 
mean of 5.1 (±3.3) months. Although the diet could be 
discontinued at parents’ discretion whenever they felt 
the burden of the diet exceeded its benefits, we urged a 
trial of the diet for at least 4 weeks. Seizure outcome of 
the patients on diet is shown in Table 3.
One patient discontinued diet before the end of the 
first month. Six patients (28.6%) discontinued the diet 
within three months. However, a total of 10 patients 
(47.6%) discontinued the diet within 6 months and only 
8 patients (38.1%) maintained on the diet beyond six 
months. Of the 21 patients, nine (42.9%) showed >50% 
reduction in seizure frequency after sixth months of diet. 
At the end of the 3rd month, the Modified Atkins Diet 
was more effective in patients with cryptogenic epilepsy 
(P=0.032). However, it was not significant at the end of 
the sixth month. 
The major reasons for discontinuing the diet were being 
ineffective in 7 patients (33.3%) and strictness of the diet 
in 3 patients (14.3%). No patient discontinued the diet 
due to abnormal laboratory results or adverse effect of 
the diet. Significant constipation was reported in four 
(19%) patients but resolved with diet modification. No 
patient developed abnormalities of white blood cell 
count, hematocrit, platelet count, BUN, creatinine, liver 
ATKINS DIET AND INTRACTABLE EPILEPSY
17Iran J Child Neurology   Vol4 No3 Nov  2010
function tests, calcium, magnesium, phosphorus or uric 
acid. Two patients showed hyperlipidemia (cholesterol 
levels of 542 mg/dL and 615 mg/dl) within the first 
month, but it was transient. 
ATKINS DIET AND INTRACTABLE EPILEPSY
Table 1: Modified Atkins Diet protocol
• Carbohydrates described in detail and restricted to 10 g/day for the first month with planned increases after 1 
month to 15 g, then 20-30 g/day as tolerated based on seizure control
• Use of fats (e.g., 36% heavy whipping cream, oils, butter, mayonnaise) encouraged
• Cereal, carbohydrate-free fluids not restricted
• Low-carbohydrate multivitamin and calcium supplementation prescribed 
• Calendar provided to document seizures daily, urine ketones semiweekly, and weight weekly
• Medications unchanged for at least the first month, but changed if necessary to tablet or sprinkle (non-liquid) 
preparations 
• Low-carbohydrate, store-bought (e.g., shakes, candy bars, baking mixes) discouraged for at least the first month
• Children evaluated in clinic after being on the diet for 1, 3, and 6 months
• Complete blood count, complete metabolic, creatinine, urea, liver function tests, uric acid, calcium, phosphorus, 
alkaline phosphatasis, fasting lipid profile and EEG evaluated at baseline, 3, and 6 months. 















1 F 1.5 LGS-symptomatic post vaccinal (pertussis) 12.2 7 3 VPA-PB-CNZ
2 M 2.9 Symptomatic-Meningitis 5.1 5 3 TPM-VPA-CBZ
3 M 1.5 Symptomatic-Cerebral Palsy 5.8 9 2 PB-VPA
4 M 6.3 Cryptogenic 8.2 9 8 VPA-PRM
5 F 5.8 Cryptogenic 7.8 6 6 PB-VPA-CNZ
6 M 3.4
Symptomatic -Hypoxic ischemic 
encephalopathy
7.5 7 1 VPA-PB-LTG
7 F 8.6 Cryptogenic 11.4 9 6 CBZ-PRM-VPA
8 M 13.00 Juvenile Myoclonic Epilepsy 14.1 5 2 VPA-LTG
9 M 3.9 Cryptogenic 9.2 4 12 CBZ-CNZ
10 M 7.5 Cryptogenic 14.3 8 9 PB-VPA-CNZ
11 F 8.1 Cryptogenic 15.4 5 7 CBZ-PRM-VPA
12 F 10.10 Juvenile Myoclonic Epilepsy 13.3 4 8 VPA-LTG-ETM
13 F 6.7 Cryptogenic 9.00 6 7 CBZ-PB-CNZ
14 F 11.2 Cryptogenic 17.00 6 6 CBZ-PB-TPM
15 M 11.00 Symptomatic-encephalitis(HSV) 15.8 4 4 VPA-LTG
16 F 6.7 Crypotogenic epilepsy 9.2 7 10 PB-CBZ
17 F 2.9 Symptomatic- Cortical dysplasia 4.7 5 3 VPA-PB-CNZ
18 M 3.1 Symptomatic-Angelman syndrome 8.5 6 1 PB-NZP-LTG
19 M 0.2 LGS-symptomatic-Tuberosis Sclerosis 4.00 11 7 PRM-NZP-VGB
20 F 6.3 Cryptogenic 11.1 14 1 VPA-LTG-NZP
21 M 4.1 Myoclonic Astatic Epilepsy of Doose 7.9 8 1 PB-VPA-NZP
 F: Female, M: Male, LGS:Lennox Gastaut Syndrome, HSV: Herpes Simplex Virus VPA: Valproic Acid, PB: Phenobarbital, 
CNZ: Clonazepam, TPM: Topiramate, CBZ: Carbamazepine, PRM: Primidone, LTG: Lamotrigine, ETM: Ethosuxamide NZP: Nitrazepam, 
VGB: Vigabatrine 
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Table 3: Condition of diet and seizure control of patients  
Seizure Reduction
Duration of diet
At first month At  third month At  sixth month
N=20(95.2%) N=15(71.4%) N=11(52.4%)
Optimal >90% 9(42.8%) 7 (33.3%) 7 (33.3%)
Effective > 50-90 % 6(28.6%) 5(23.8%) 2(9.5%)
ineffective < 50 % 5 (23.8%) 3(14.3%) 2(9.5%)
Discussion
The Modified Atkins Diet (MAD) was created at 
Johns Hopkins Hospital as an attempt to create a more 
palatable and less restrictive dietary treatment primarily 
for children with behavioral difficulties and adolescents 
in whom parents and neurologists were reluctant to start 
the traditional ketogenic diet (KD). Since there was 
only limited evidence that high ratios of calorie and 
fluid restriction, fasting, and an inpatient diet initiation 
were necessary for ketogenic diet (12-13), the MAD 
was designed to induce ketosis while providing similar 
foods but with unlimited quantities of fat and protein. 
Kossoff et al., 2003, first reported a case series of six 
children and adults with intractable epilepsy who were 
treated with the Modified Atkins Diet. Half of these 
patients showed at least a 50% reduction in seizures 
(10).
  We showed that the Modified Atkins Diet could be a 
dietary alternative for the classic KD in children with 
intractable epilepsy. Six months after initiating the 
modified Atkins Diet, 52.4% of the patients remained 
on the diet and 42.9% experienced > 50% reduction in 
seizures.   
 Our overall results are similar to a study from South 
Korea on 14 children aged 2-14 years with intractable 
epilepsy, demonstrating that six months after the 
initiation of the diet, 50% of the patients remained 
on the diet and 36% experienced > 50% reduction in 
seizures (14). However, the first formal prospective 
study on the use of Modified Atkins Diet for epilepsy 
reported much better results since 80% of the patients 
were able to stay on the diet, 65% experienced > 50% 
response, and 19% became seizure- free after 6  months 
(11). Results of  a study in Iran on 24 children with 
intractable epilepsy showed that three months after 
diet initiation, 67% of the patients had  >50% decrease 
in seizure frequency which was more than our study. 
This finding could be explained by the longer duration 
of diet in our study (15). In a prospective open-label 
study on 30 adult patients with an age range of 18 to 53 
years, 47% of the patients experienced >50% seizure 
reduction after 1 and 3 months of diet and 33% of 
the patients showed >50% seizure reduction after 6 
months (16). Porta et al retrospectively compared the 
KD and MAD in 27 children with intractable epilepsy 
and concluded that both the KD and MAD had similar 
efficacy in children with intractable epilepsy in a 6-
month period; however, the MAD was better tolerated 
(17). Although characteristics of the patients have not 
been predictive of diet response in most studies, we 
noted that patients with cryptogenic epilepsy had a 
better outcome (P=0.032).
 Although the results of most studies regarding the efficacy 
of the Modified Atkins Diet as therapy for intractable 
epilepsy are average, the seizure reduction induced 
by the diet is similar to most trials of new adjunctive 
anticonvulsants for adults with intractable epilepsy with 
33-47% of patients having >50% seizure reduction 
over the study period (18). Unfortunately, the costs and 
the lack of availability of the new anticonvulsants in 
developing countries can be problematic.
The most common reason for discontinuing the diet was 
neither the lack of acceptance (or tolerance) of the diet 
nor the difficulty of diet preparation, but because the diet 
was not sufficiently effective in 33.3% of our patients. 
If seizures substantially reduced (>50%), the probability 
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of remaining on the diet at 6 months was high. If seizure 
control was <50%, it correlated with a decreasing percent 
of patients remaining on the diet in the course of time. 
Virtually, most (80%) of those who remained on the diet 
for 6 months had >50% seizure control; and virtually all 
of those who had good seizure control remained on the 
diet.
The MAD appears to be tolerable with limited adverse 
effects in recent studies. The increase in total cholesterol, 
blood urea nitrogen and urine calcium/creatinine ratio 
have been previously reported but usually do not lead 
to diet discontinuation (11, 14, 19). In our study, two 
patients showed hyperlipidemia which was transient 
and successfully managed by careful follow-up and 
conservative strategies. Weight loss may occur in 
children and adults who are predominantly overweight 
and may be desired. 
Unlike the KD, the long-term side effects of the MAD 
are not clear. Considering the increased protein and 
decreased fat content, it is possible that the risk of 
growth impairment, kidney stones, dyslipidemia, and 
gastroesophageal reflux be less compared to the KD. 
It can be concluded that the Modified Atkins Diet is a 
safe and effective alternative therapy for intractable 
childhood epilepsy. This diet can replace the conventional 
KD, especially in older children and adolescents. 
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